A STUDY OF PHARMACOLOGY OF 17-HYDROXYPROGESTERONE CAPROATE IN PREGNANCY

17-羟基孕酮己酸酯在妊娠期的药理学研究

• 批准号: 7608457
• 负责人: MENACHEM MIODOVNIK
• 金额: $ 2.19万
• 依托单位: GEORGETOWN UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2007
• 资助国家: 美国
• 起止时间: 2007-05-01 至 2008-03-31
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7608457
• 关键词: Computer Retrieval of Information on Scientific Projects Database; Drug Kinetics; Drug Transport; Enrollment; Funding; Grant; Hydroxyprogesterone Caproate; Injection of therapeutic agent; Institution; Length; Metabolism; National Institute of Child Health and Human Development; Participant; Pharmacology; Pregnancy; Pregnant Women; Premature Labor; Research; Research Personnel; Resources; Site; Source; Time; United States National Institutes of Health; Week; prevent

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. This is a multi-center NICHD funded study, conducted by the Obstetrical Pharmacology Research Unit (OPRU) network, to define the pharmacology of 17-OHPC in pregnancy: its pharmacokinetics, metabolism and placental transport of the drug. 17-OHPC is used to prevent preterm labor. Sixty pregnant women will be studied three times during their pregnancies (two PK studies, and placental transport during labor & delivery), along with an optional fourth study. There will be 15 participants at the GU site. Participants will receive weekly IM injections of 17-OHPC from enrollment until 35 weeks gestation, with length of participation in study about 15 weeks.

该副本是利用众多研究子项目之一 由NIH/NCRR资助的中心赠款提供的资源。子弹和 调查员（PI）可能已经从其他NIH来源获得了主要资金， 因此可以在其他清晰的条目中代表。列出的机构是 对于中心，这不一定是调查员的机构。 这是一项由产科药理学研究部（OPRU）网络进行的多中心NICHD资助的研究，旨在定义妊娠17-OHPC的药理学：其药代动力学，代谢和胎盘运输的药物。 17-OHPC用于防止早产。在怀孕期间将对六十名孕妇进行三次研究（两次PK研究和胎盘 人工和分娩期间的运输），以及可选的第四项研究。 GU网站将有15名参与者。参与者将每周从入学人数到妊娠35周进行每周IM注射17-OHPC的注射，参与研究的时间约为15周。